BEN GURION CANAL PROJECT COMPILATION (5 SHORTS) https://www.bitchute.com/video/v3gIOdVF5MEY/
ISRAEL'S PLAN TO BUILD A NEW MASSIVE CANAL THROUGH GAZA. https://www.bitchute.com/video/VphzFXyv21Pk/
THE BEN GURION CANAL: EXPOSING THE GAZA GENOCIDE https://www.bitchute.com/video/t5qpbULP17N7/
BEN GURION CANAL PROJECT | ISRAEL'S MOTIVES BEHIND GAZA WAR https://www.bitchute.com/video/3y2XWaV1sZaU/
WHY ISRAEL WANTS TO BUILD THE BEN GURION CANAL THAT CUTS THROUGH GAZA https://www.bitchute.com/video/m86Xla1OeS4O/
GAZA LAND GRAB THE BEN GURION CANAL PLAN – VIDEO #42 https://www.bitchute.com/video/9dcAQifq8Brc/
BEN GURION CANAL & LAVANT OIL RESERVES - THE REAL.REASON FOR THE GAZA GENOCIDE BY ISRAEL https://www.bitchute.com/video/qyGH8aojeKYN/
Executive Order 13887—Modernizing Influenza Vaccines in the United States To Promote National Security and Public Health September 19, 2019 By the authority vested in me as President by the Constitution and the laws of the United States of America, including section 301 of title 3, United States Code, it is hereby ordered as follows:
Section 1. Findings. (a) Influenza viruses are constantly changing as they circulate globally in humans and animals. Relatively minor changes in these viruses cause annual seasonal influenza outbreaks, which result in millions of illnesses, hundreds of thousands of hospitalizations, and tens of thousands of deaths each year in the United States. Periodically, new influenza A viruses emerge from animals, including birds and pigs, that can spread efficiently and have sustained transmission among humans. This situation is called an influenza pandemic (pandemic). Unlike seasonal influenza, a pandemic has the potential to spread rapidly around the globe, infect higher numbers of people, and cause high rates of illness and death in populations that lack prior immunity. While it is not possible to predict when or how frequently a pandemic may occur, there have been 4 pandemics in the last 100 years. The most devastating pandemic occurred in 1918–1919 and is estimated to have killed more than 50 million people worldwide, including 675,000 Americans.
(b) Vaccination is the most effective defense against influenza. Despite recommendations by the Centers for Disease Control and Prevention (CDC) that nearly every American should receive the influenza vaccine annually, however, seasonal influenza vaccination levels in the United States have currently reached only about 45 percent of CDC goals.
(c) All influenza vaccines presently in use have been developed for circulating or anticipated influenza viruses. These vaccines must be reformulated for each influenza season as well as in the event of a pandemic. Additional research is needed to develop influenza vaccines that provide more effective and longer-lasting protection against many or all influenza viruses.
(d) The current domestic enterprise for manufacturing influenza vaccines has critical shortcomings. Most influenza vaccines are made in chicken eggs, using a 70-year-old process that requires months-long production timelines, limiting their utility for pandemic control; rely on a potentially vulnerable supply chain of eggs; require the use of vaccine viruses adapted for growth in eggs, which could introduce mutations of the influenza vaccine virus that may render the final product less effective; and are unsuitable for efficient and scalable continuous manufacturing platforms.
(e) The seasonal influenza vaccine market rewards manufacturers that deliver vaccines in time for the influenza season, without consideration of the speed or scale of these manufacturers' production processes. This approach is insufficient to meet the response needs in the event of a pandemic, which can emerge rapidly and with little warning. Because the market does not sufficiently reward speed, and because a pandemic has the potential to overwhelm or compromise essential government functions, including defense and homeland security, the Government must take action to promote faster and more scalable manufacturing platforms.
Sec. 2. Policy. It is the policy of the United States to modernize the domestic influenza vaccine enterprise to be highly responsive, flexible, scalable, and more effective at preventing the spread of influenza viruses. This is a public health and national security priority, as influenza has the potential to significantly harm the United States and our interests, including through large-scale illness and death, disruption to military operations, and damage to the economy. This order directs actions to reduce the United States' reliance on egg-based influenza vaccine production; to expand domestic capacity of alternative methods that allow more agile and rapid responses to emerging influenza viruses; to advance the development of new, broadly protective vaccine candidates that provide more effective and longer lasting immunities; and to support the promotion of increased influenza vaccine immunization across recommended populations.
Sec. 3. National Influenza Vaccine Task Force. (a) There is hereby established a National Influenza Vaccine Task Force (Task Force). The Task Force shall identify actions to achieve the objectives identified in section 2 of this order and monitor and report on the implementation and results of those actions. The Task Force shall be co-chaired by the Secretary of Defense and the Secretary of Health and Human Services, or their designees.
(b) In addition to the Co-Chairs, the Task Force shall consist of a senior official from the following executive branch departments, agencies, and offices:
(i) the Department of Defense (DOD);
(ii) the Department of Justice;
(iii) the Department of Agriculture;
(iv) the Department of Veterans Affairs (VA);
(v) the Department of Homeland Security;
(vi) the United States Food and Drug Administration;
(vii) the Centers for Disease Control and Prevention;
(viii) the National Institutes of Health (NIH);
(ix) the Centers for Medicare and Medicaid Services (CMS); and
(x) the Biomedical Advanced Research and Development Authority (BARDA).
(c) The Co-Chairs may jointly invite additional Federal Government representatives, with the consent of the applicable executive department, agency, or office head, to attend meetings of the Task Force or to become members of the Task Force, as appropriate.
(d) The staffs of the Department of State, the Office of Management and Budget (OMB), the National Security Council, the Council of Economic Advisers, the Domestic Policy Council, the National Economic Council, and the Office of Science and Technology Policy (OSTP) may attend and participate in any Task Force meetings or discussions.
(e) The Task Force may consult with State, local, tribal, and territorial government officials and private sector representatives, as appropriate and consistent with applicable law.
(f) Within 120 days of the date of this order, the Task Force shall submit a report to the President, through the Assistant to the President for National Security Affairs, the Assistant to the President for Domestic Policy, the Director of the Office of Management and Budget, and the Director of the Office of Science and Technology Policy. The report shall include:
(i) a 5-year national plan (Plan) to promote the use of more agile and scalable vaccine manufacturing technologies and to accelerate development of vaccines that protect against many or all influenza viruses;
(ii) recommendations for encouraging non-profit, academic, and private-sector influenza vaccine innovation; and (iii) recommendations for increasing influenza vaccination among the populations recommended by the CDC and for improving public understanding of influenza risk and informed influenza vaccine decision-making.
(g) Not later than June 1 of each of the 5 years following submission of the report described in subsection (f) of this section, the Task Force shall submit an update on implementation of the Plan and, as appropriate, new recommendations for achieving the policy objectives set forth in section 2 of this order.
Sec. 4. Agency Implementation. The heads of executive departments and agencies shall also implement the policy objectives defined in section 2 of this order, consistent with existing authorities and appropriations, as follows:
(a) The Secretary of HHS shall:
(i) through the Assistant Secretary for Preparedness and Response and BARDA:
(A) estimate the cost of expanding and diversifying domestic vaccine-manufacturing capacity to use innovative, faster, and more scalable technologies, including cell-based and recombinant vaccine manufacturing, through cost-sharing agreements with the private sector, which shall include an agreed-upon pricing strategy during a pandemic;
(B) estimate the cost of expanding domestic production capacity of adjuvants in order to combine such adjuvants with both seasonal and pandemic influenza vaccines;
(C) estimate the cost of expanding domestic fill-and-finish capacity to rapidly fulfill antigen and adjuvant needs for pandemic response;
(D) estimate the cost of developing, evaluating, and implementing delivery systems to augment limited supplies of needles and syringes and to enable the rapid and large-scale administration of pandemic influenza vaccines;
(E) evaluate incentives for the development and production of vaccines by private manufacturers and public-private partnerships, including, in emergency situations, the transfer of technology to public-private partnerships—such as the HHS Centers for Innovation and Advanced Development and Manufacturing or other domestic manufacturing facilities—in advance of a pandemic, in order to be able to ensure adequate domestic pandemic manufacturing capacity and capability;
(F) support, in coordination with the DOD, NIH, and VA, a suite of clinical studies featuring different adjuvants to support development of improved vaccines and further expand vaccine supply by reducing the dose of antigen required; and
(G) update, in coordination with other relevant public health agencies, the research agenda to dramatically improve the effectiveness, efficiency, and reliability of influenza vaccine production;
(ii) through the Director of NIH, provide to the Task Force estimated timelines for implementing NIH's strategic plan and research agenda for developing influenza vaccines that can protect individuals over many years against multiple types of influenza viruses;
(iii) through the Commissioner of Food and Drugs:
(A) further implement vaccine production process improvements to reduce the time required for vaccine production (e.g., through the use of novel technologies
for vaccine seed virus development and through implementation of improved potency and sterility assays);
(B) develop, in conjunction with the CDC, proposed alternatives for the timing of vaccine virus selection to account for potentially shorter timeframes associated with non egg based manufacturing and to facilitate vaccines optimally matched to the circulating strains;
(C) further support the conduct, in collaboration with the DOD, BARDA, and CDC, of applied scientific research regarding developing cell lines and expression systems that markedly increase the yield of cell-based and recombinant influenza vaccine manufacturing processes; and
(D) assess, in coordination with BARDA and relevant vaccine manufacturers, the use and potential effects of using advanced manufacturing platforms for influenza vaccines;
(iv) through the Director of the CDC:
(A) expand vaccine effectiveness studies to more rapidly evaluate the effectiveness of cell based and recombinant influenza vaccines relative to egg-based vaccines;
(B) explore options to expand the production capacity of cell-based vaccine candidates used by industry;
(C) develop a plan to expand domestic capacity for whole genome characterization of influenza viruses;
(D) increase influenza vaccine use through enhanced communication and by removing barriers to vaccination; and
(E) enhance communication to healthcare providers about the performance of influenza vaccines, in order to assist them in promoting the most effective vaccines for their patient populations; and
(v) through the Administrator of CMS, examine the current legal, regulatory, and policy framework surrounding payment for influenza vaccines and assess adoption of domestically manufactured vaccines that have positive attributes for pandemic response (such as scalability and speed of manufacturing).
(b) The Secretary of Defense shall:
(i) provide OMB with a cost estimate for transitioning DOD's annual procurement of influenza vaccines to vaccines manufactured both domestically and through faster, more scalable, and innovative technologies;
(ii) direct, in coordination with the VA, CDC, and other components of HHS, the conduct of epidemiological studies of vaccine effectiveness to improve knowledge of the clinical effect of the currently licensed influenza vaccines;
(iii) use DOD's network of clinical research sites to evaluate the effectiveness of licensed influenza vaccines, including methods of boosting their effectiveness;
(iv) identify opportunities to use DOD's vaccine research and development enterprise, in collaboration with HHS, to include both early discovery and design of influenza vaccines as well as later-stage evaluation of candidate influenza vaccines;
(v) investigate, in collaboration with HHS, alternative correlates of immune protection that could facilitate development of next-generation influenza vaccines; (vi) direct the conduct of a study to assess the feasibility of using DOD's advanced manufacturing facility for manufacturing cell-based or recombinant influenza vaccines during a pandemic; and
(vii) accelerate, in collaboration with HHS, research regarding rapidly scalable prophylactic influenza antibody approaches to complement a universal vaccine initiative and address gaps in current vaccine coverage.
(c) The Secretary of VA shall provide OMB with a cost estimate for transitioning its annual procurement of influenza vaccines to vaccines manufactured both domestically and with faster, more scalable, and innovative technologies.
Sec. 5. Termination. The Task Force shall terminate upon direction from the President or, with the approval of the President, upon direction from the Task Force Co-Chairs.
Sec. 6. General Provisions. (a) Nothing in this order shall be construed to impair or otherwise affect:
(i) the authority granted by law to an executive department or agency, or the head thereof; or
(ii) the functions of the Director of the Office of Management and Budget relating to budgetary, administrative, or legislative proposals.
(b) This order shall be implemented consistent with applicable law and subject to the availability of appropriations.
(c) This order is not intended to, and does not, create any right or benefit, substantive or procedural, enforceable at law or in equity by any party against the United States, its departments, agencies, or entities, its officers, employees, or agents, or any other person.
DONALD J. TRUMP
The White House,
September 19, 2019.
NOTE: This Executive order was published in the Federal Register on September 24.
Donald J. Trump, Executive Order 13887—Modernizing Influenza Vaccines in the United States To Promote National Security and Public Health Online by Gerhard Peters and John T. Woolley, The American Presidency Project https://www.presidency.ucsb.edu/node/333869
Tim Kelly Interviews Dr. Alan Sabrosky-Consultant Specializing in National and International Security Affairs. A Marine Corps Vietnam Veteran and a 1986 Graduate of the U.S. Army War College
https://www.podomatic.com/podcasts/tkelly6785757/episodes/2024-04-25T15_08_05-07_00
Dr. Sabrosky is a writer and consultant specializing in national and international security affairs. A Marine Corps Vietnam veteran and a 1986 graduate of the U.S. Army War College. He has held concurrent adjunct professorships at Georgetown University and the Johns Hopkins University School of Advanced International Studies. His published work includes thirteen books among which includes are Alliances in U.S. Foreign Policy, The Recourse to War: An Appraisal of the "Weinberger Doctrine", and Prisoners of War? Nation-States in the Modern Era.
Dr. Alan Sabrosky returns to the show to discuss Israel’s ethnic cleansing in Gaza and the Jewish state’s apparent control of U.S. foreign policy, and the destructive influence the Jewish Lobby enjoys over our country's political establishment. We also talk about whether the events of the past 6 months represent a Jewish Apocalypse.
https://www.unz.com/runz/israeli-assassinations-and-public-scrutiny/
** AUDIO**: https://www.unz.com/CONTENTS/AUDIO/runz/Unz-IsraeliAssassinations.mp3?_=1
EXCERPT: The ongoing Israel/Gaza conflict just passed the six month mark, an astonishing development that almost no one would have imagined at the time it first began.
The length of the fighting is without precedent across the last seventy-five years of Israeli military history. In 1956, Israel allied itself with Britain and France and suddenly attacked Egypt, conquering the Sinai in a war that lasted little more than a week. Israel’s 1967 surprise attack against Egypt, Syria, and Jordan achieved complete military victory in just six days. Then Egypt and Syria returned the favor in 1973 and came close to overrunning Israel until an unprecedented American military resupply airlift allowed Israel to turn the tide and win a decisive military victory in less than three weeks. The main fighting in Israel’s 1982 invasion of Lebanon only took a couple of weeks, while its 2006 invasion of that same country lasted about a month and its 2008 assault on Gaza was even shorter. Most of these previous half-dozen campaigns were fought against heavily-equipped conventional armies but their combined length totaled considerably less than the time Israel has now spent trying to defeat Gaza’s lightly-armed Hamas militants.
Furthermore, Israel’s lack of battlefield success against the entrenched Hamas fighters has become rather obvious. Few if any of the Israelis captured in the October 7th raid have been successfully freed and none of Hamas’ top commanders have been killed or captured. The extent of Hamas’ battlefield losses is unclear, but since the group consists entirely of adult males and the demographic profile of the Gazans reported killed seems very close to that of Gaza’s general civilian population, it seems likely that only a small fraction of Hamas’ 30,000 combat troops have fallen. Indeed, Israel’s failure to capture almost any Hamas members has led to grotesque incidents in which the Israelis seized and stripped male Gazan civilians and falsely paraded them around as captured Hamas militants for a propaganda video.
WHO IS RON UNZ? A theoretical physicist by training, Mr. Unz serves as founder and chairman of UNZ.org, a content-archiving website providing free access to many hundreds of thousands of articles from prominent periodicals of the last hundred and fifty years. He also served as publisher of The American Conservative, a small opinion magazine, from 2006 to 2013 and had previously served as chairman of Wall Street Analytics, Inc., a financial services software company which he founded in New York City in 1987. He holds undergraduate and graduate degrees from Harvard University, Cambridge University, and Stanford University, and is a past first-place winner in the Intel/Westinghouse Science Talent Search. He was born in Los Angeles in 1961.
He has long been deeply interested in public policy issues, and his writings on issues of immigration, race, ethnicity, and social policy have appeared in The New York Times, The Wall Street Journal, Commentary, The Nation, and numerous other publications.
In 1994, he launched a surprise Republican primary challenge to incumbent Gov. Pete Wilson of California, running on a conservative, pro-immigrant platform against the prevailing political sentiment, and received 34% of the vote. Later that year, he campaigned as a leading opponent of Prop. 187, the anti-immigration initiative, and was a top featured speaker at a 70,000 person pro-immigrant march in Los Angeles, the largest political rally in California history to that date.
In 1997, Mr. Unz began his “English for the Children” initiative campaign to dismantle bilingual education in California. He drafted Prop. 227 and led the campaign to qualify and pass the measure, culminating in a landslide 61% victory in June 1998, effectively eliminating over one-third of America’s bilingual programs. Within less than three years of the new English immersion curriculum, the mean percentile test scores of over a million immigrant students in California rose by an average of 70%. He later organized and led similar initiative campaigns in other states, winning with 63% in the 2000 Arizona vote and a remarkable 68% in the 2002 Massachusetts vote without spending a single dollar on advertising.
After spending most of the 2000s focused on software projects, he has recently become much more active in his public policy writings, most of which have appeared in his own magazine. Major recent articles include:
Main takeaway: I’m new to this subject, and after writing this article and letting it age for a day or two (always a good idea when you venture into something new and complicated), I realized that the best insight I’ve had since reading up on this and trying to make sense of it, is that massive US security state funding of bioweapons for decades has created a ‘blob’ which has gobbled up huge sections of society – including big pharma and our medical system. Our vaccine addiction is very much a result of this biowar funding. Here, I’m borrowing heavily from the ideas of Mike Benz who has described a similar phenomenon in the ‘censorship industrial complex’.
I am convinced that Benz’s work is a hugely important event which is still underestimated. It got major exposure due to a recent Tucker video, and people are starting to catch on. I can’t urge you enough to follow him on Twitter and understand what he is saying. His links and the Tucker video are below in the article. One of Benz’s central insights is that massive security state funding for years, and the need to bypass laws, leads to a ‘whole of society’ phenomenon, where the security state coopts entire sectors of society – media, academia, government, IT, etc. – in order to pursue their censorship goals. He calls it ‘the blob’. He dates its beginnings from 2016.
While thinking about this whole bioweapons / vaccine connection, I realized that it is very similar. In this case the massive funding has been going on for decades, and it has been much larger. The result of both is equally dangerous – to me, shutting down free speech is as bad as being poisoned by bioweapons and vaxes.
Here’s the article I originally wrote. The most important insight is the parallel with Benz’s ideas.